Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

逸沃 - NMPA Drug Approval Details

Approvals/NMPA/Ipilimumab Injection

Approved

生物制品

Ipilimumab Injection

Bristol-Myers Squibb Pharma EEIG🇨🇳 National Medical Products Administration

Approval Date: Jun 8, 2021
Approval ID: 887B9Qti4Hy
Company: Bristol-Myers Squibb Pharma EEIG
Type: 生物制品

Approval Details

Approval Id: 887B9Qti4Hy
Approval Number: 国药准字SJ20210019
Generic Name: 伊匹木单抗注射液
Generic Name En: Ipilimumab Injection
Trade Name: 逸沃
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 50mg（10ml）/瓶
Reg Date: 2021-06-08
Expired Date: 2026-06-07
Company Name: Bristol-Myers Squibb Pharma EEIG
Company Detail Path: /organization/bristol-myers-squibb-pharma-eeig

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jun 8, 2021

Approval ID

887B9Qti4Hy

Type

生物制品

Back to NMPA Approvals